Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial

  • STATUS
    Recruiting
  • days left to enroll
    20
  • participants needed
    30
  • sponsor
    Fudan University
Updated on 22 March 2022
hormone therapy

Summary

By incorporating dual-tracer PET/CT (PSMA and FDG) and ctDNA, we aimed to evaluate lesion heterogeneity and genomic change of mCRPC patients receiving novel hormonal therapy. The relationship between treatment response and different molecular characterization, as well as imaging features would also be evaluated.

Details
Condition Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Disease
Treatment prednisone, Abiraterone, Androgen Deprivation Therapy
Clinical Study IdentifierNCT05188911
SponsorFudan University
Last Modified on22 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Diagnosed as mCRPC according to EAU-ESTRO-SIOG 2016 and PSA > 10ng/ml
No previous treatment with novel hormonal therapy
ECOG 0-2
Normal organ function, WBC >= 3000/mm3 or Neutrophil >= 1500/mm3
Aged 18 to 85 years old when issuing written informed consent
Life expectancy > 12 months
Consent and able to carry out follow-up visit and cooperate with all other study procedures

Exclusion Criteria

Severe disease or other medical conditions suggesting a high risk of death within 1 year, which may interfere with follow-up. Decided by investigator
Diagnosed with any other malignant tumor within 3 years before enrollment
Unable to provide necessary follow-up information
Other conditions that are judged as ineligible by the investigator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note